AviadoBio

MRI of the brain
#AviadoBio #Dementia #Gene therapy #Neurodegenerative disorders #Phase II trial

Gene therapy trial starts in early-onset dementia

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. ASPIRE-FTD is evaluating investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). The study is also recruiting in Europe with… Read More

#News

Canary Wharf, London
#AviadoBio #Biotech hubs #Laboratory #London #London Innovation Centre #Neuroscience

Life sciences hub at Canary Wharf sees rapid growth

Kadans’ London Innovation Centre at Canary Wharf, London has launched its wet lab innovation and flexible workspace centre and welcomed a new tenant. AviadoBio, a gene therapy company developing medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. The… Read More

#News